Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends for Bio-Rad Laboratories, Inc. With me on the call today are Norman D.

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...

Q1 2025 Management View CEO Norman Schwartz noted that despite macroeconomic headwinds, the company is focusing on long-term opportunities in life science research and diagnostics markets. Schwartz ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Bio-Rad Laboratories, Inc. stands amongst them. Bio-Rad Laboratories, Inc. (NYSE:BIO), a global ...

Have you looked into how Bio-Rad Laboratories (BIO) performed internationally during the quarter ending March 2025? Considering the widespread global presence of this maker of instruments used in ...

Bio-Rad Laboratories, Inc. BIO posted first-quarter 2024 adjusted earnings per share (EPS) of $2.29, beating the Zacks Consensus Estimate by 12.3%. However, the bottom line declined 31.4% from the ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has ...